Treace Medical Concepts to Announce Third Quarter Results
PONTE VEDRA, Fla. — Treace Medical Concepts, Inc. (NASDAQ: TMCI) is a leading medical technology company that specializes in transforming the surgical treatment of bunions and similar midfoot deformities. The company has announced plans to disclose its financial results for the third quarter of 2025 following the conclusion of trading on Thursday, November 6, 2025.
Conference Call for Financial Results
Treace’s management team will hold a conference call to discuss the financial outcomes beginning at 4:30 pm ET. This call offers a valuable opportunity for viewers to gain insight into the company's financial performance and strategic direction going forward.
How to Join the Conference Call
For those interested in participating, pre-registration is required. Investors can register online to receive specific dial-in instructions and a unique pin number to join the discussion. This interactive session allows participants to engage directly with company leadership, providing a forum for questions regarding the financial results.
Company Overview
Treace Medical Concepts focuses on enhancing the surgical management standards for bunions and related midfoot deformities. Bunions affect around 65 million individuals in the United States, with approximately 1.1 million qualifying for surgical intervention annually. Treace has developed an innovative solution, the Lapiplasty® 3D Bunion Correction® System, aimed at addressing the multi-dimensional aspects of bunion deformities, which are primarily caused by an unstable joint within the foot.
Innovative Surgical Solutions
The company's patented technology is designed not only to correct the bunion but also to stabilize the affected joint, helping patients return to their active routines. Additionally, Treace has expanded its offerings with other systems, such as the Adductoplasty® Midfoot Correction System and the SpeedMTP® Rapid Compression Implant, which target various types of bunion presentations and minimize the complexity during surgical procedures.
Investing in Future Technologies
Treace Medical is innovating in the foot and ankle sector by introducing the SpeedPlate® Rapid Compression Implants, a versatile solution applicable for various surgical procedures, emphasizing on bone fusion needs. This commitment to advancing surgical options reflects the company’s focus on improving patient outcomes and expanding its impact on the medical landscape.
Stay Updated with Treace
Investors and potential clients are encouraged to regularly visit Treace's investor relations website for the latest updates, performance data, and other critical information. The company actively shares significant insights through its online platforms, reinforcing its commitment to transparency and investor engagement.
Connect with Treace
For further inquiries or to learn more about Treace Medical Concepts and its innovative approaches, stakeholders can connect on platforms like LinkedIn, X, Facebook, and Instagram to stay informed about the company’s advancements and initiatives.
Frequently Asked Questions
What is the date for Treace's Q3 financial results announcement?
The financial results for Q3 will be announced on November 6, 2025, after trading closes.
How can investors participate in the conference call?
Investors need to pre-register to obtain dial-in numbers and a unique pin for the conference call.
What does Treace specialize in?
Treace Medical Concepts specializes in surgical methods and technologies for treating bunions and related foot deformities.
What innovative products does Treace offer?
The company has developed several systems including the Lapiplasty® 3D Bunion Correction® System and SpeedMTP® Rapid Compression Implant.
How can I get updates from Treace?
Visit their investor relations website or follow them on social media platforms for the latest updates and information.
